Work

Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20253s04myx7

Authors: James A. Tumlin, Rajesh Yalavarthy, Dong Ki Kim, Ju young Moon, Inwhee Park, Sung Gyun Kim, Sreedhar A. Mandayam, Frank B. Cortazar, Amanda M. Enstrom, Heather Thomas, Jiahua Li, Yih-Chieh Chen, Stanford L Peng, Jason Leigh Sanders, Ogo I. Egbuna, Arvind Madan

Institutions: Emory University, Seoul National University Hospital, Kyung Hee University Hospital at Gangdong, Ajou University, Hallym University Sacred Heart Hospital, The University of Texas MD Anderson Cancer Center, Vertex Pharmaceuticals (United States)

Language: English

Topic: Renal Diseases and Glomerulopathies

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4416876014

FWCI: 0.602

Cites:

Cited by: 1

Related to: